国际肿瘤学杂志

国际肿瘤学杂志 ›› 2013, Vol. 40 ›› Issue (3): 191-192.

• 综述 • 上一篇    下一篇

Regorafenib治疗恶性肿瘤的研究进展

葛蒙晰, 梁晓华   

  1. 200040 复旦大学附属华山医院肿瘤科；复旦大学上海医学院肿瘤学系

  • 出版日期:2013-03-08 发布日期:2013-02-25
  • 基金资助:

    国家自然科学基金资助项目（81101551）

Regorafenib in the treatment of malignant tumor

GE  Meng-Xi, LIANG  Xiao-Hua   

  1. Department of Oncology, Huashan Hospital, Fudan University, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

  • Online:2013-03-08 Published:2013-02-25

PDF

1617

摘要： Regorafenib(BAY73-4506）是一种口服多激酶抑制剂，可以靶向作用于血管源性、间质源性及致癌性等多种酪氨酸激酶。在体外及临床试验中Regorafenib均显示出显著的抗肿瘤活性。在恶性实体瘤特别是结直肠肿瘤的治疗中，Regorafenib的临床试验结果令人鼓舞。

关键词: 受体蛋白质酪氨酸激酶类, 酶抑制剂, 肿瘤

Abstract: Regorafenib, an oral multi-kinase inhibitor, can inhabit a class of receptor tyrosine kinase, such as angiogenic, stromal, oncogenic and so on. Studies in vitro and clinical trials indicate that regorafenib has significant antitumor activity. The results of clinical trials are encouraging for the treatment of refractory solid tumors, especially for colorectal carcinoma.

Key words: Receptor protein-tyrosine kinases, Enzyme inhibitors, Neoplasms